First and Best-in-Class Breakthrough Oral Therapies to Reverse Retinal Neurodegenerative Diseases

About us

SunRegen Healthcare AG

A Swiss Basel-Area based bio-pharmaceutical company developing novel and neuro-rescuing therapies to treat and reverse retinal and central nerve neurodegenerative diseases.

Our first drug candidate is in development for Retinitis Pigmentosa (RP) and in evaluation for other retinal neurodegenerative diseases including Dry Age-Related Macular Degeneration, Primary Optic Atrophy and Glaucoma Optic Atrophy. We initially focus on retinal diseases with huge unmet medical needs and blockbuster potentials, and then expanding into central nerve / neuromuscular diseases such as Alzheimer, Huntington, Parkinson and ALS diseases.

Read More

our Dream

SunRegen's Vision

Bring best-in-class, life-changing therapies to all patients suffering from retinal and central nervous system neurodegenerative diseases, ensuring innovative, effective, and accessible treatments that improve quality of life, restore vision, and provide renewed hope through advanced research, compassionate care, and a commitment to transforming outcomes for those affected by these debilitating conditions.

teamates

Our Team

Dr. Dong has 12 years of scientific drug development experiences at Novartis. She worked for the development of over 10 drugs including Tyzeka (Telbivudine), which was approved by the US FDA in October 2006 to treat chronic hepatitis B (HBV). She has won four Novartis Awards and published over 30 papers on internationally renowned journals.

Chairman, founder

Dr. Yuhong Dong

Dr. Dong has 12 years of scientific drug development experiences at Novartis. She worked for the development of over 10 drugs including Tyzeka (Telbivudine), which was approved by the US FDA in October 2006 to treat chronic hepatitis B (HBV). She has won four Novartis Awards and published over 30 papers on internationally renowned journals.

Managing Director, founder

David Guan

Dr. Dong has 12 years of scientific drug development experiences at Novartis. She worked for the development of over 10 drugs including Tyzeka (Telbivudine), which was approved by the US FDA in October 2006 to treat chronic hepatitis B (HBV). She has won four Novartis Awards and published over 30 papers on internationally renowned journals.

Director

Dr. Hubert Wong

Dr. Dong has 12 years of scientific drug development experiences at Novartis. She worked for the development of over 10 drugs including Tyzeka (Telbivudine), which was approved by the US FDA in October 2006 to treat chronic hepatitis B (HBV). She has won four Novartis Awards and published over 30 papers on internationally renowned journals.

Advisor

Dr. Philip Bentley

Dr. Dong has 12 years of scientific drug development experiences at Novartis. She worked for the development of over 10 drugs including Tyzeka (Telbivudine), which was approved by the US FDA in October 2006 to treat chronic hepatitis B (HBV). She has won four Novartis Awards and published over 30 papers on internationally renowned journals.

Advisor

Dr. Matthias Staufenbiel

Dr. Dong has 12 years of scientific drug development experiences at Novartis. She worked for the development of over 10 drugs including Tyzeka (Telbivudine), which was approved by the US FDA in October 2006 to treat chronic hepatitis B (HBV). She has won four Novartis Awards and published over 30 papers on internationally renowned journals.

Advisor

Dr Francois Jenck

Achievements

Our Awards

  • Grant from Innosuisse, Swiss Federal Innovation Agency -- Over 1 million CHF in total.
  • Grant from SME Instrument of EU Horizontal 2020 Program, Phase 1 supported 50K EURO.
  • Grant from Baselaunch, a Swiss biopharma Incubator provided funding, office and other resources.
  • Winner of the Johnson & Johnson sponsored Startup Slam competition at the 2018 BIO-Europe.
  • Winner of MAGINE IF Innovation Forum.
  • Approved by J&J to become a residence of JLABS.

Board of

Governance

Audit Committee

Mr. Hong Yu, Mr. William Johnson, Mr. David Guan

Compensation Committee

Mr. William Johnson, Mr. Hong Yu, Mr. David Guan

Nomination Committee

Mr. Hong Yu, Mr. William Johnson, Dr. Yuhong Dong

Partnership

Our Partners

SunRegen Healthcare AG is leveraging the global pharmaceutical development ecosystem and building partnerships with professional CROs/CMOs, academic institutions, and service organizations related to pharmaceutical development.

Career

Welcome experienced scientists from the CNS and retinal field or industry experts for preclinical/clinical development to contact us. Please send your CV and motivation letter.
HR@sunregen.ch
Scroll to Top